U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07315373) titled 'Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia' on Dec. 18, 2025.
Brief Summary: The goal of this clinical trial is to find the best dose of zanubrutinib when used together with high-dose dexamethasone for adults who are newly diagnosed with primary immune thrombocytopenia (ITP), and to learn how safe and effective this combination treatment is.
Study Start Date: Dec. 25, 2025
Study Type: INTERVENTIONAL
Condition:
Immune Thrombocytopenia
Intervention:
DRUG: Zanubrutinib 80mg/d
Zanubrutinib: 80 mg taken orally once daily for 26 weeks
DRUG: High dose dexamethasone
Dexamethasone: 40 mg taken orally once dai...